Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
AstraZeneca
Moodys
Merck
McKinsey

Last Updated: December 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for OTO-104

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for OTO-104?

OTO-104 is an investigational drug.

There have been 23 clinical trials for OTO-104. The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2015.

The most common disease conditions in clinical trials are Meniere Disease, Otitis, and Otitis Media. The leading clinical trial sponsors are Otonomy, Inc., Assiut University, and OHSU Knight Cancer Institute.

There are two US patents protecting this investigational drug and forty-four international patents.

Recent Clinical Trials for OTO-104
TitleSponsorPhase
OTO-413 in Subjects With Speech-in-Noise Hearing ImpairmentOtonomy, Inc.Phase 1/Phase 2
OTO-313 in Subjects With Subjective TinnitusOtonomy, Inc.Phase 1/Phase 2
Phase 3 Study of OTO-104 in Subjects With Unilateral Meniere's DiseaseOtonomy, Inc.Phase 3

See all OTO-104 clinical trials

Clinical Trial Summary for OTO-104

Top disease conditions for OTO-104
Top clinical trial sponsors for OTO-104

See all OTO-104 clinical trials

US Patents for OTO-104

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
OTO-104   Start Trial 11-substituted bile acid derivatives, process for the preparation thereof and use of these compounds as medicaments Council of Scientific and Industrial Research (New Delhi, IN)   Start Trial
OTO-104   Start Trial Low, immune enhancing, dose mtor inhibitors and uses thereof Novartis AG (Basel, CH)   Start Trial
OTO-104   Start Trial Therapeutic compounds and methods of use thereof GENENTECH, INC. (South San Francisco, CA) XENON PHARMACEUTICALS INC. (Burnaby, BC, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Express Scripts
McKesson
Moodys
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.